Table 3.
The correlation between pathological parameters and GSTM3 expression.
| Characteristic | Low expression of GSTM3 | High expression of GSTM3 | p |
|---|---|---|---|
| n | 189 | 190 | |
| FIGO stage, n (%) | 1.000 | ||
| Stage I | 1 (0.3%) | 0 (0%) | |
| Stage II | 12 (3.2%) | 11 (2.9%) | |
| Stage III | 147 (39.1%) | 148 (39.4%) | |
| Stage IV | 28 (7.4%) | 29 (7.7%) | |
| Primary therapy outcome, n (%) | 0.182 | ||
| PD | 16 (5.2%) | 11 (3.6%) | |
| SD | 7 (2.3%) | 15 (4.9%) | |
| PR | 19 (6.2%) | 24 (7.8%) | |
| CR | 113 (36.7%) | 103 (33.4%) | |
| Race, n (%) | 0.699 | ||
| Asian | 7 (1.9%) | 5 (1.4%) | |
| Black or African American | 11 (3%) | 14 (3.8%) | |
| White | 166 (45.5%) | 162 (44.4%) | |
| Age, n (%) | 0.324 | ||
| <=60 | 109 (28.8%) | 99 (26.1%) | |
| >60 | 80 (21.1%) | 91 (24%) | |
| Histologic grade, n (%) | 0.285 | ||
| G1 | 0 (0%) | 1 (0.3%) | |
| G2 | 19 (5.1%) | 26 (7%) | |
| G3 | 164 (44.4%) | 158 (42.8%) | |
| G4 | 0 (0%) | 1 (0.3%) | |
| Anatomic neoplasm subdivision, n (%) | 1.000 | ||
| Unilateral | 52 (14.6%) | 50 (14%) | |
| Bilateral | 129 (36.1%) | 126 (35.3%) | |
| Venous invasion, n (%) | 0.177 | ||
| No | 18 (17.1%) | 23 (21.9%) | |
| Yes | 38 (36.2%) | 26 (24.8%) | |
| Lymphatic invasion, n (%) | 0.133 | ||
| No | 21 (14.1%) | 27 (18.1%) | |
| Yes | 59 (39.6%) | 42 (28.2%) | |
| Tumor residual, n (%) | 0.495 | ||
| NRD | 30 (9%) | 37 (11%) | |
| RD | 135 (40.3%) | 133 (39.7%) | |
| Tumor status, n (%) | 0.641 | ||
| Tumor free | 33 (9.8%) | 39 (11.6%) | |
| With tumor | 132 (39.2%) | 133 (39.5%) | |
| Age, meidan (IQR) | 58 (49, 67) | 60 (51, 71) | 0.086 |